nach oben

Current HIV/AIDS Reports

Erschienen in:

10.09.2016 | Co-infections and Comorbidity (S Naggie, Section Editor)

HIV, Aging, and Viral Coinfections: Taking the Long View

verfasst von: Tamar H. Taddei, Vincent Lo Re 3rd, Amy C. Justice

Erschienen in: Current HIV/AIDS Reports | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Viral suppression of human immunodeficiency virus (HIV) with combination antiviral therapy (cART) has led to increasing longevity but has not enabled a complete return to health among aging HIV-infected individuals (HIV+). Viral coinfections are prevalent in the HIV+ host and are implicated in cancer, liver disease, and accelerated aging. We must move beyond a simplistic notion of HIV becoming a “chronic controllable illness” and develop an understanding of how viral suppression alters the natural history of HIV infection, especially at the intersection of HIV with other common viral coinfections in the context of an altered, aging immune system.

Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet. 2014;384:241–8.PubMedCrossRef

Prejean J, Song R, Hernandez A, Ziebell R, Green T, Walker F, et al. Estimated HIV incidence in the United States, 2006–2009. PLoS One. 2011;6:e17502.PubMedPubMedCentralCrossRef

Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166:1632–41.PubMedCrossRef

4.••

Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373:705–13.PubMedPubMedCentralCrossRef

5.••

Osinusi A, Townsend K, Kohli A, Nelson A, Seamon C, Meissner EG, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA. 2015;313:1232–9.PubMedCrossRef

6.••

Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, et al. Daclatasvir plus Sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373:714–25.PubMedCrossRef

7.••

Sulkowski MS, Eron JJ, Wyles D, Trinh R, Lalezari J, Wang C, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015;313:1223–31. These four references [4••–7••] are the landmark clinical trials demonstrating that second generation direct acting antiviral therapies are highly effective in patients with HIV/HCV coinfection, curing > 94% of patients, similar to the results seen in monoinfected patients.PubMedCrossRef

Childs K, Taylor C, Dieterich D, Agarwal K. Directly acting antivirals for hepatitis C virus arrive in HIV/hepatitis C virus co-infected patients: from’mind the gap’ to’where’s the gap?’. AIDS. 2016;30:975–89.PubMedCrossRef

9.•

Korf BR, Rehm HL. New approaches to molecular diagnosis. JAMA. 2013;309:1511–21.PubMedCrossRef

10.•

Ashley EA. The precision medicine initiative: a new national effort. JAMA. 2015;313:2119–20.PubMedCrossRef

11.•

Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372:793–5. These three references [9•–11•] describe the techniques involved [9•] and the focus [9•–10•] of genomic or “precision medicine”. President Obama’s Precision Medicine Initiative promises Federal funding to promote research to improve our understanding of and to drive change in the fields of oncology, pharmacology, and prevention.PubMedCrossRef

12.••

Effros RB. The silent war of CMV in aging and HIV infection. Mech Ageing Dev 2015. This paper is a thorough and thoughtful synthesis of the science of CMV and senescence, providing important insights into the effect of CMV on cellular immunity and age-related morbidity.

13.

Park LS, Tate JP, Justice AC, Lo Re 3rd V, Lim JK, Brau N, et al. FIB-4 index is associated with hepatocellular carcinoma risk in HIV-infected patients. Cancer Epidemiol Biomarkers Prev. 2011;20:2512–7.PubMedPubMedCentralCrossRef

14.

Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med. 2008;148:728–36.PubMedCrossRef

15.

Crum-Cianflone N, Hullsiek KH, Marconi V, Weintrob A, Ganesan A, Barthel RV, et al. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS. 2009;23:41–50.PubMedPubMedCentralCrossRef

16.

Silverberg MJ, Chao C, Leyden WA, Xu L, Tang B, Horberg MA, et al. HIV infection and the risk of cancers with and without a known infectious cause. AIDS. 2009;23:2337–45.PubMedPubMedCentralCrossRef

17.••

Park LS, Hernandez-Ramirez RU, Silverberg MJ, Crothers K, Dubrow R. Prevalence of non-HIV cancer risk factors in persons living with HIV/AIDS: a meta-analysis. AIDS. 2016;30:273–91. This paper is an exhaustive meta-analysis assessing non-HIV cancer risk factors in HIV+ in 113 publications. This analysis quantifies the high prevalence of smoking, HPV, HCV, and HBV in this population.PubMedCrossRef

18.••

Lo Re 3rd V, Kallan MJ, Tate JP, Localio AR, Lim JK, Goetz MB, et al. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med. 2014;160:369–79. This study in 4280 HIV+/HCV+ on cART compared to 6079 HCV monoinfected individuals showed higher rates of hepatic decompensation among HIV+. Coinfected patients with baseline advanced liver fibrosis, severe anemia, diabetes, and nonblack race experienced higher rates of decompensation.PubMed

19.

Thio CL, Seaberg EC, Skolasky Jr R, Phair J, Visscher B, Munoz A, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002;360:1921–6.PubMedCrossRef

20.

Gilson RJ, Hawkins AE, Beecham MR, Ross E, Waite J, Briggs M, et al. Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS. 1997;11:597–606.PubMedCrossRef

21.

Colin JF, Cazals-Hatem D, Loriot MA, Martinot-Peignoux M, Pham BN, Auperin A, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology. 1999;29:1306–10.PubMedCrossRef

22.••

Chen JY, Feeney ER, Chung RT. HCV and HIV co-infection: mechanisms and management. Nat Rev Gastroenterol Hepatol. 2014;11:362–71. This comprehensive review explains the mechanisms involved in accelerated fibrosis in patients with HIV/HCV coinfection. There is a helpful discussion on the pathways leading to hepatic fibrosis. There are two instructive figures, one on the pathogenesis of liver disease in HIV+/HCV+ and the other on viral interactions in the hepatocyte.PubMedPubMedCentralCrossRef

23.•

Lim JK, Tate JP, Fultz SL, Goulet JL, Conigliaro J, Bryant KJ, et al. Relationship between alcohol use categories and noninvasive markers of advanced hepatic fibrosis in HIV-infected, chronic hepatitis C virus-infected, and uninfected patients. Clin Infect Dis. 2014;58:1449–58. This paper shows the association between increasing rates of alcohol consumption and increasing severity of fibrosis. Advanced hepatic fibrosis was more common among HIV-infected than uninfected independent of level of alcohol use.PubMedPubMedCentralCrossRef

24.

Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33:562–9.PubMedCrossRef

25.

Pineda JA, Romero-Gomez M, Diaz-Garcia F, Giron-Gonzalez JA, Montero JL, Torre-Cisneros J, et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology. 2005;41:779–89.PubMedCrossRef

26.

Brau N, Fox RK, Xiao P, Marks K, Naqvi Z, Taylor LE, et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol. 2007;47:527–37.PubMedCrossRef

27.

Lin W, Weinberg EM, Chung RT. Pathogenesis of accelerated fibrosis in HIV/HCV co-infection. J Infect Dis. 2013;207 Suppl 1:S13–8.PubMedPubMedCentralCrossRef

28.

Morishima C, Paschal DM, Wang CC, Yoshihara CS, Wood BL, Yeo AE, et al. Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing. Hepatology. 2006;43:573–80.PubMedCrossRef

29.

Lin W, Weinberg EM, Tai AW, Peng LF, Brockman MA, Kim KA, et al. HIV increases HCV replication in a TGF-beta1-dependent manner. Gastroenterology. 2008;134:803–11.PubMedCrossRef

30.•

Ryom L, Lundgren JD, De Wit S, Kovari H, Reiss P, Law M, et al. Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons. AIDS 2016. In this cohort of 49,000 patients the authors observed an increased incidence of ESLD/HCC among those with cumulative exposure to d4T, ddI, tenofovir, and (fos)amprenavir. Longer exposure to emtricitabine and nevirapine were associated with lower ESLD/HCC rates. The ddI/d4T-associated increased ESLD/HCC rate only started to decline 6 years after cessation. Mechanisms of drug toxicity and the potential for long lasting effects must be further expored.

31.

Sahasrabuddhe VV, Shiels MS, McGlynn KA, Engels EA. The risk of hepatocellular carcinoma among individuals with acquired immunodeficiency syndrome in the United States. Cancer. 2012;118:6226–33.PubMedPubMedCentralCrossRef

32.

Ioannou GN, Bryson CL, Weiss NS, Miller R, Scott JD, Boyko EJ. The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection. Hepatology. 2013;57:249–57.PubMedCrossRef

33.

Merchante N, Merino E, Lopez-Aldeguer J, Jover F, Delgado-Fernandez M, Galindo MJ, et al. Increasing incidence of hepatocellular carcinoma in HIV-infected patients in Spain. Clin Infect Dis. 2013;56:143–50.PubMedCrossRef

34.

Montes Ramirez ML, Miro JM, Quereda C, Jou A, von Wichmann MA, Berenguer J, et al. Incidence of hepatocellular carcinoma in HIV-infected patients with cirrhosis: a prospective study. J Acquir Immune Defic Syndr. 2014;65:82–6.PubMedCrossRef

35.

Sherman M. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis. 2010;30:3–16.PubMedCrossRef

36.

El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118–27.PubMedCrossRef

37.

Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245–55.PubMedCrossRef

38.

El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745–50.PubMedCrossRef

39.••

El-Serag HB, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology. 2014;60:1767–75. This paper provides insights into the changing epidemiology of HCC in the US, including the ever increasing burden of obesity and its association with these trends. A figure depicting time-trends of HCC by age groups and birth cohorts in the United States shows both the heterogeneity and south to north gradient of HCC incidence rates.PubMedPubMedCentralCrossRef

40.

Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis. 2002;34:831–7.PubMedCrossRef

41.

Raymond HF, Hughes A, O’Keefe K, Stall RD, McFarland W. Hepatitis C prevalence among HIV-positive MSM in San Francisco: 2004 and 2008. Sex Transm Dis. 2011;38:219–20.PubMedCrossRef

42.

Giordano TP, Kramer JR, Souchek J, Richardson P, El-Serag HB. Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992–2001. Arch Intern Med. 2004;164:2349–54.PubMedCrossRef

43.

Park LS, Tate JP, Rodriguez-Barradas MC, Rimland D, Goetz MB, Gibert C, et al. Cancer incidence in HIV-infected versus uninfected veterans: comparison of cancer registry and ICD-9 code diagnoses. J AIDS Clin Res. 2014;5:1000318.PubMedPubMedCentral

44.

Berretta M, Garlassi E, Cacopardo B, Cappellani A, Guaraldi G, Cocchi S, et al. Hepatocellular carcinoma in HIV-infected patients: check early, treat hard. Oncologist. 2011;16:1258–69.PubMedPubMedCentralCrossRef

45.

Bourcier V, Winnock M, Ait Ahmed M, Sogni P, Pambrun E, Poizot-Martin I, et al. Primary liver cancer is more aggressive in HIV-HCV coinfection than in HCV infection. A prospective study (ANRS CO13 Hepavih and CO12 Cirvir). Clin Res Hepatol Gastroenterol. 2012;36:214–21.PubMedCrossRef

46.

Gramenzi A, Tedeschi S, Cantarini MC, Erroi V, Tumietto F, Attard L, et al. Outcome of hepatocellular carcinoma in human immunodeficiency virus-infected patients. Dig Liver Dis. 2013;45:516–22.PubMedCrossRef

47.

Yopp AC, Subramanian M, Jain MK, Mansour JC, Schwarz RE, Balch GC, et al. Presentation, treatment, and clinical outcomes of patients with hepatocellular carcinoma, with and without human immunodeficiency virus infection. Clin Gastroenterol Hepatol. 2012;10:1284–90.PubMedPubMedCentralCrossRef

48.••

Althoff KN, McGinnis KA, Wyatt CM, Freiberg MS, Gilbert C, Oursler KK, et al. Comparison of risk and age at diagnosis of myocardial infarction, end-stage renal disease, and non-AIDS-defining cancer in HIV-infected versus uninfected adults. Clin Infect Dis. 2015;60:627–38. In this cohort of nearly 100,000 subjects (~30 HIV+, ~70% uninfected), the authors report a greater risk of MI, ESRD, and non-AIDS cancers in HIV+ compared with uninfected adults. These comorbidities occurred at similar ages in both groups.PubMedCrossRef

49.••

Robbins HA, Pfeiffer RM, Shiels MS, Li J, Hall HI, Engels EA. Excess cancers among HIV-infected people in the United States. J Natl Cancer Inst. 2015; 107. Using data from the HIV/AIDS Cancer Match (HACM) Study and the Surveillance, Epidemiology, and End Results program, the authors show a decline in the proportion of excess cancers that were AIDS defining (ie, KS, NHL, cervical cancer) with age and time since AIDS diagnosis. They observe a high rate of anal cancers in men who have sex with men, and high rates of lung and liver cancer among injection drug users.

50.•

Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546–55. This is a systematic review and pooled analysis of global data on HBV prevalance. The authors note the wide variation in prevalence and quality of data collection between countries and highlight the need for preventive measures and consistent data collection.PubMedCrossRef

51.

McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis. 2011;15:223–43. vii-x.PubMedPubMedCentralCrossRef

52.

Kellerman SE, Hanson DL, McNaghten AD, Fleming PL. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis. 2003;188:571–7.PubMedCrossRef

53.

Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS. 2005;19:593–601.PubMedCrossRef

54.

Lee HC, Ko NY, Lee NY, Chang CM, Ko WC. Seroprevalence of viral hepatitis and sexually transmitted disease among adults with recently diagnosed HIV infection in Southern Taiwan, 2000–2005: upsurge in hepatitis C virus infections among injection drug users. J Formos Med Assoc. 2008;107:404–11.PubMedCrossRef

55.

Diop-Ndiaye H, Toure-Kane C, Etard JF, Lo G, Diaw P, Ngom-Gueye NF, et al. Hepatitis B, C seroprevalence and delta viruses in HIV-1 Senegalese patients at HAART initiation (retrospective study). J Med Virol. 2008;80:1332–6.PubMedCrossRef

56.

Nyirenda M, Beadsworth MB, Stephany P, Hart CA, Hart IJ, Munthali C, et al. Prevalence of infection with hepatitis B and C virus and coinfection with HIV in medical inpatients in Malawi. J Infect. 2008;57:72–7.PubMedCrossRef

57.

Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73.PubMedCrossRef

58.••

Wu CY, Lin JT, Ho HJ, Su CW, Lee TY, Wang SY, et al. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. Gastroenterology. 2014;147:143–151 e145. This nationwide cohort study from Taiwan demonstates a reduced risk of HCC in patients with chronic HBV treated with nucleoside analogue therapy, providing further evidence of the feasibility of cancer prevention in this population in which HBV is highly prevalent.PubMedCrossRef

59.

Soriano V, Puoti M, Peters M, Benhamou Y, Sulkowski M, Zoulim F, et al. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS. 2008;22:1399–410.PubMedCrossRef

60.•

Fernandez-Montero JV, Vispo E, Barreiro P, Sierra-Enguita R, de Mendoza C, Labarga P, et al. Hepatitis delta is a major determinant of liver decompensation events and death in HIV-infected patients. Clin Infect Dis. 2014;58:1549–53.PubMedCrossRef

61.•

Romeo R, Foglieni B, Casazza G, Spreafico M, Colombo M, Prati D. High serum levels of HDV RNA are predictors of cirrhosis and liver cancer in patients with chronic hepatitis delta. PLoS One. 2014;9:e92062. These papers [60• and 61•] provide further evidence that chronic hepatitis delta is associated with higher rates of cirrhosis and poorer outcomes in both HIV+ and uninfected patients.PubMedPubMedCentralCrossRef

62.

Bruix J, Sherman M, American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–2.PubMedPubMedCentralCrossRef

63.••

Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150:835–53. This paper is a comprehensive and insightful review of the state of the science of HCC, stage specific therapeutic guidelines, and treatments in development.PubMedCrossRef

64.

European Association For The Study Of The L, European Organisation For R, Treatment Of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–43.CrossRef

65.••

Raffetti E, Fattovich G, Donato F. Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and meta-analysis. Liver Int. 2016. This paper is a systemic review and meta-analysis of 66 studies with over 340,000 patients showing a signficantly higher incidence of HCC according to HBV status (symptomatic carrier, chronic hepatitis and compensated cirrhosis compared to inactive carrier), but, interestingly, not for geographical area after adjusting for age. Alcohol intake ≥60 g/dl and HBV genotype C were also associated with higher incidence of HCC.

66.••

Lo Re 3rd V, Schuster M. Evaluating hepatitis B virus reactivation during solid tumor chemotherapy: evidence to guide pretreatment hepatitis B screening and prophylaxis. Ann Intern Med. 2016;164:64–5.PubMedCrossRef

67.••

Perrillo RP, Martin P, Lok AS. Preventing hepatitis B reactivation due to immunosuppressive drug treatments. JAMA. 2015;313:1617–8. These papers [66•• and 67••] underscore the importance of screening for HBV prior to initiating immunosuppressive therapy. Both papers highlight the low uptake of HBV screening by oncologists and review the data showing the benefit of antiviral prophylaxis in reducing the risk for HBV reactivation in patients with chronic HBV receiving immunosuppressive therapy for cancer.PubMedCrossRef

68.••

Soriano V, Labarga P, de Mendoza C, Pena JM, Fernandez-Montero JV, Benitez L, et al. Emerging challenges in managing hepatitis B in HIV patients. Curr HIV/AIDS Rep. 2015;12:344–52. This paper is a synthesis of the literature and an insightful look at challenges of managing hepatitis B in HIV+. The authors focus on the challenges of failure to suppress HBV viral load, viral breakthrough and reactivations. They highlight the importance of screening for liver cancer and they explore the complexity of viral coinfection (HCV, HDV).PubMedCrossRef

69.

Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29:4294–301.PubMedPubMedCentralCrossRef

70.

Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011;103:753–62.PubMedPubMedCentralCrossRef

71.

Silverberg MJ, Lau B, Justice AC, Engels E, Gill MJ, Goedert JJ, et al. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis. 2012;54:1026–34.PubMedPubMedCentralCrossRef

72.

Dubrow R, Silverberg MJ, Park LS, Crothers K, Justice AC. HIV infection, aging, and immune function: implications for cancer risk and prevention. Curr Opin Oncol. 2012;24:506–16.PubMedPubMedCentralCrossRef

73.

Beachler DC, D’Souza G, Sugar EA, Xiao W, Gillison ML. Natural history of anal vs oral HPV infection in HIV-infected men and women. J Infect Dis. 2013;208:330–9.PubMedPubMedCentralCrossRef

74.

Beachler DC, Weber KM, Margolick JB, Strickler HD, Cranston RD, Burk RD, et al. Risk factors for oral HPV infection among a high prevalence population of HIV-positive and at-risk HIV-negative adults. Cancer Epidemiol Biomarkers Prev. 2012;21:122–33.PubMedCrossRef

75.•

Robbins HA, Fennell CE, Gillison M, Xiao W, Guo Y, Wentz A, et al. Prevalence of and Risk Factors for Oral Human Papillomavirus Infection among HIV-Positive and HIV-Negative People Who Inject Drugs. PLoS One. 2015;10:e0143698. This cross-sectional study of 199 people who inject drugs, found no association between recent drug use and oral HPV prevalence. Risk factors for oral HPV infection included being HIV+ and recently performing oral sex on a woman.PubMedPubMedCentralCrossRef

76.•

Beachler DC, Sugar EA, Margolick JB, Weber KM, Strickler HD, Wiley DJ, et al. Risk factors for acquisition and clearance of oral human papillomavirus infection among HIV-infected and HIV-uninfected adults. Am J Epidemiol. 2015;181:40–53. This longitudinal cohort study demonstrates higher risk of incident oral HPV infection in those with HIV infection, reduced current CD4 cell count, and increased numbers of oral sex partners. Factors associated with persistent infection were male sex, older age, and current smoking.PubMedCrossRef

77.

Dayton AI, Sodroski JG, Rosen CA, Goh WC, Haseltine WA. The trans-activator gene of the human T cell lymphotropic virus type III is required for replication. Cell. 1986;44:941–7.PubMedCrossRef

78.

Ott M, Emiliani S, Van Lint C, Herbein G, Lovett J, Chirmule N, et al. Immune hyperactivation of HIV-1-infected T cells mediated by Tat and the CD28 pathway. Science. 1997;275:1481–5.PubMedCrossRef

79.

Westendorp MO, Shatrov VA, Schulze-Osthoff K, Frank R, Kraft M, Los M, et al. HIV-1 Tat potentiates TNF-induced NF-kappa B activation and cytotoxicity by altering the cellular redox state. EMBO J. 1995;14:546–54.PubMedPubMedCentral

80.

Kim RH, Yochim JM, Kang MK, Shin KH, Christensen R, Park NH. HIV-1 Tat enhances replicative potential of human oral keratinocytes harboring HPV-16 genome. Int J Oncol. 2008;33:777–82.PubMed

81.

Tugizov SM, Herrera R, Chin-Hong P, Veluppillai P, Greenspan D, Michael Berry J, et al. HIV-associated disruption of mucosal epithelium facilitates paracellular penetration by human papillomavirus. Virology. 2013;446:378–88.PubMedCrossRef

82.

Shoham N, Cohen L, Yaniv A, Gazit A. The Tat protein of the human immunodeficiency virus type 1 (HIV-1) interacts with the EGF-like repeats of the Notch proteins and the EGF precursor. Virus Res. 2003;98:57–61.PubMedCrossRef

83.•

Zhong R, Bao R, Faber PW, Bindokas VP, Bechill J, Lingen MW, et al. Notch1 Activation or Loss Promotes HPV-Induced Oral Tumorigenesis. Cancer Res. 2015;75:3958–69.PubMedPubMedCentralCrossRef

84.•

Lee SH, Do SI, Lee HJ, Kang HJ, Koo BS, Lim YC: Notch1 signaling contributes to stemness in head and neck squamous cell carcinoma. Lab Invest 2016. Both papers [82• and 83•] demonstrate relationships between HPV and Notch1 signaling and explore the role of Notch1 in the pathogenesis of head and neck cancer.

85.

van Manen D, Wout AB, Schuitemaker H. Genome-wide association studies on HIV susceptibility, pathogenesis and pharmacogenomics. Retrovirology. 2012;9:70.PubMedPubMedCentralCrossRef

86.

Joshi D, O’Grady J, Dieterich D, Gazzard B, Agarwal K. Increasing burden of liver disease in patients with HIV infection. Lancet. 2011;377:1198–209.PubMedCrossRef

87.

Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2006;44:S6–9.PubMedCrossRef

88.

Lopez-Dieguez M, Montes ML, Pascual-Pareja JF, Quereda C, Von Wichmann MA, Berenguer J, et al. The natural history of liver cirrhosis in HIV-hepatitis C virus-coinfected patients. AIDS. 2011;25:899–904.PubMedCrossRef

89.•

Marcellin F, Roux P, Loko MA, Lions C, Caumont-Prim A, Dabis F, et al. High levels of alcohol consumption increase the risk of advanced hepatic fibrosis in HIV/hepatitis C virus-coinfected patients: a sex-based analysis using transient elastography at enrollment in the HEPAVIH ANRS CO13 cohort. Clin Infect Dis. 2014;59:1190–2.PubMedCrossRef

90.•

Bailony MR, Scherzer R, Huhn G, Plankey MW, Peters MG, Tien PC. Association of HIV infection, hepatitis C virus infection, and metabolic factors with liver stiffness measured by transient elastography. J Infect Dis. 2013;208:1776–83. These studies [89• and 90•] underscore the effect of alcohol [89•] and metabolic factors [90•] in accelerating liver fibrosis; both studies use noninvasive markers of fibrosis, specifically measuring liver stiffness with transient elastography.PubMedPubMedCentralCrossRef

91.

Merchante N, Rivero A, de Los S-GI, Merino D, Marquez M, Lopez-Ruz MA, et al. Insulin resistance is associated with liver stiffness in HIV/HCV co-infected patients. Gut. 2009;58:1654–60.PubMedCrossRef

92.••

Mandorfer M, Payer BA, Schwabl P, Steiner S, Ferlitsch A, Aichelburg MC, et al. Revisiting liver disease progression in HIV/HCV-coinfected patients: the influence of vitamin D, insulin resistance, immune status, IL28B and PNPLA3. Liver Int. 2015;35:876–85. This is a comprehensive and insightful review of the many factors at play in acclerating progression of fibrosis in HIV/HCV coinfected patients.PubMedCrossRef

93.

Reiberger T, Ferlitsch A, Sieghart W, Kreil A, Breitenecker F, Rieger A, et al. HIV-HCV co-infected patients with low CD4+ cell nadirs are at risk for faster fibrosis progression and portal hypertension. J Viral Hepat. 2010;17:400–9.PubMedCrossRef

94.

Anderson JP, Tchetgen Tchetgen EJ, Lo Re 3rd V, Tate JP, Williams PL, Seage 3rd GR, et al. Antiretroviral therapy reduces the rate of hepatic decompensation among HIV- and hepatitis C virus-coinfected veterans. Clin Infect Dis. 2014;58:719–27.PubMedCrossRef

95.

Sanmartin R, Tor J, Sanvisens A, Lopez JJ, Jou A, Muga R, et al. Progression of liver fibrosis in HIV/hepatitis C virus-coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline. HIV Med. 2014;15:203–12.PubMedCrossRef

96.

van der Helm J, Geskus R, Sabin C, Meyer L, Del Amo J, Chene G, et al. Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997. Gastroenterology. 2013;144:751–60. e752.PubMedCrossRef

97.••

AASLD/IDSA: HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C: http://www.hcvguidelines.org/full-report/unique-patient-populations-patients-hivhcv-coinfection. Accessed 3/6/16. These guidelines are jointly authored by the AASLD/IDSA and offer up-to-date treatment recommendations for HCV according to genotype with attention to important details such as prior treatment status, renal disease, and HIV coinfection. The site is continually updated and is an excellent reference for everyday clinical treatment decisionmaking.

98.

Merchante N, Giron-Gonzalez JA, Gonzalez-Serrano M, Torre-Cisneros J, Garcia-Garcia JA, Arizcorreta A, et al. Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS. 2006;20:49–57.PubMedCrossRef

99.

Chen J, Florian J, Carter W, Fleischer RD, Hammerstrom TS, Jadhav PR, et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology. 2013;144:1450–5. e1452.PubMedCrossRef

100.•

Sulkowski MS, Naggie S, Lalezari J, Fessel WJ, Mounzer K, Shuhart M, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA. 2014;312:353–61. This is the landmark study that assessed the efficacy of an all-oral, interferon-free regimen for HCV genotypes 1, 2, and 3 in patients coinfected with HIV. Although published in 2014, the treatment regimen is obsolete for genotype 1, and paper should be viewed through the “historical” lens of the importance of involving HIV+ early on in such trials.PubMedPubMedCentralCrossRef

101.

Kwo PY, Agrawal S. HCV/HIV Coinfection: A New Treatment Paradigm. Gastroenterology. 2015;148:1470–1.PubMedCrossRef

102.

Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010;52:833–44.PubMedPubMedCentralCrossRef

103.

van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584–93.PubMedCrossRef

104.

Labarga P, Fernandez-Montero JV, de Mendoza C, Barreiro P, Soriano V. Long-term survival and liver-related events after pegylated interferon/ribavirin therapy in HIV-infected patients with chronic hepatitis C. Antivir Ther. 2015;20:65–72.PubMedCrossRef

105.

Aleman S, Rahbin N, Weiland O, Davidsdottir L, Hedenstierna M, Rose N, et al. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis. 2013;57:230–6.PubMedCrossRef

106.

Zator ZA, Chung RT. After the cure: management of HCV after achievement of SVR. Curr HIV/AIDS Rep. 2013;10:428–35.PubMedCrossRef

107.•

Lu M, Li J, Zhang T, Rupp LB, Trudeau S, Holmberg SD, Moorman AC, Spradling PR, Teshale EH, Xu F, et al.: Long-Term Reduction in Liver Fibrosis, Based on Serum Biomarkers, in Patients With Sustained Viral Responses to Hepatitis C Virus Treatment. Clin Gastroenterol Hepatol 2016.

108.•

Cohort ACH: Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among HIV/HCV-coinfected patients. AIDS 2015, 29:1821–1830. Both studies [106• and 107•] show the beneficial effect of SVR after HCV therapy on regression of fibrosis using noninvasive markers of fibrosis. The endpoint of regression of fibrosis is emerging in importance in study design for HCV trials.

109.••

Collins JM, Raphael KL, Terry C, Cartwright EJ, Pillai A, Anania FA, et al. Hepatitis B virus reactivation during successful treatment of hepatitis C virus with Sofosbuvir and Simeprevir. Clin Infect Dis. 2015;61:1304–6. This paper highlights the phenomenon of HBV reactivation during DAA therapy for HCV, a phenomenon that was not seen in the interferon era due to interferon’s activity agains HBV. It is essential to be aware of HBV status prior to initiating HCV therapy in order to assess risk of reactivation and to consider prophylactic HBV suppression.PubMedCrossRef

110.

Parrinello CM, Sinclair E, Landay AL, Lurain N, Sharrett AR, Gange SJ, et al. Cytomegalovirus immunoglobulin G antibody is associated with subclinical carotid artery disease among HIV-infected women. J Infect Dis. 2012;205:1788–96.PubMedPubMedCentralCrossRef

111.

Naeger DM, Martin JN, Sinclair E, Hunt PW, Bangsberg DR, Hecht F, et al. Cytomegalovirus-specific T cells persist at very high levels during long-term antiretroviral treatment of HIV disease. PLoS One. 2010;5, e8886.PubMedPubMedCentralCrossRef

112.•

Rector JL, Thomas GN, Burns VE, Dowd JB, Herr RM, Moss PA, et al. Elevated HbA(1c) levels and the accumulation of differentiated T cells in CMV(+) individuals. Diabetologia. 2015;58:2596–605. This study demonstrated the association between unfavourable glucose and lipid profiles with accumulation of dCTLs in CMV(+) individuals. No associations were observed in CMV(−) individuals. These findings suggest CMV infection may be a modifier of metabolic risk factors in development of disease.PubMedPubMedCentralCrossRef

113.••

Pathai S, Bajillan H, Landay AL. High KP: is HIV a model of accelerated or accentuated aging? J Gerontol A Biol Sci Med Sc. 2014;69:833–42. This is an insightful review of the evidence that HIV accelerates age-related clinical syndromes. The authors explore HIV as a model of premature aging, considering the complexity of the interactions between antiretroviral therapy, modifiable risk factors (eg, smoking, substance abuse, alcohol) and coinfection in HIV+.CrossRef

Titel: HIV, Aging, and Viral Coinfections: Taking the Long View
verfasst von: Tamar H. Taddei
Vincent Lo Re 3rd
Amy C. Justice
Publikationsdatum: 10.09.2016
Verlag: Springer US
Erschienen in: Current HIV/AIDS Reports / Ausgabe 5/2016
Print ISSN: 1548-3568
Elektronische ISSN: 1548-3576
DOI: https://doi.org/10.1007/s11904-016-0327-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2016

Metabolic Complications and Glucose Metabolism in HIV Infection: A Review of the Evidence

Atherosclerotic Cardiovascular Disease and Anti-Retroviral Therapy

Community-Based Interventions to Improve and Sustain Antiretroviral Therapy Adherence, Retention in HIV Care and Clinical Outcomes in Low- and Middle-Income Countries for Achieving the UNAIDS 90-90-90 Targets

Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV

Guidelines for Evaluation and Management of Cognitive Disorders in HIV-Positive Individuals